글로벌 연구동향
방사선종양학
- 2021년 12월호
[Int J Radiat Oncol Biol Phys.] The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis 간외담도암에서 보조적 항암화학방사선치료: 장기추적관찰 분석결과서울의대 / 장원익, 지의규*
- 출처
- Int J Radiat Oncol Biol Phys.
- 등재일
- 2021 Oct 1
- 저널이슈번호
- 111(2):395-404. doi: 10.1016/j.ijrobp.2021.05.012.
- 내용
Abstract
Purpose: Despite frequent use in the clinical setting, especially for patients with high-risk factors for relapse, the role of adjuvant treatment has not been clarified in nonhilar extrahepatic bile duct cancer (NH-EHBDC). The goal of this study is to identify the role of adjuvant chemoradiotherapy (CRT) in NH-EHBDC patients after radical surgery.Methods and materials: Patients with NH-EHBDC who underwent radical surgery from July 2007 to December 2018 were reviewed retrospectively. Univariate and multivariate analyses were conducted to identify prognostic factors for locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Subgroup analyses were performed to further identify the role of adjuvant CRT.
Results: Three hundred twenty-eight patients were accrued. At a median follow-up of 37.1 months (range, 1.0-144.2 months), the 3-year LRRFS, DMFS, DFS, and OS were 63.4%, 59.0%, 53.2%, and 67.5%, respectively. In multivariate analysis, adjuvant CRT was an independent prognostic factor for LRRFS, DMFS, DFS, and OS (P < .05). For patients with nodal involvement, pT3 stage, tumor size ≥ 5 cm, poorly differentiated tumor, and R1 resection, adjuvant CRT significantly improved DFS (P < .05).
Conclusions: In patients with NH-EHBDC, adjuvant CRT significantly improved LRRFS and DFS. For patients with risk factors such as nodal involvement, pT3 stage, poorly differentiated tumor, tumor size ≥ 5 cm, or R1 resection, adjuvant CRT might contribute to improve treatment outcomes.
Affiliations
Won Ick Chang 1 , Byoung Hyuck Kim 2 , Hyun-Cheol Kang 1 , Kyubo Kim 3 , Kyung-Hun Lee 4 , Do-Youn Oh 4 , Hongbeom Kim 5 , Wooil Kwon 5 , Jin-Young Jang 5 , Eui Kyu Chie 6
1 Department of Radiation Oncology, Seoul National University College of Medicine.
2 Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University, Boramae Medical Center.
3 Department of Radiation Oncology, Ewha Womans University College of Medicine.
4 Department of Internal Medicine, Seoul National University College of Medicine.
5 Department of Surgery, Seoul National University College of Medicine.
6 Department of Radiation Oncology, Seoul National University College of Medicine; Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea. Electronic address: ekchie93@snu.ac.kr.
- 덧글달기
- 이전글 [Eur J Surg Oncol.] Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases
- 다음글 [Cancer Res Treat.] Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae
편집위원
간외담도암 중 간문부 이하에 위치한 종양에서 근치적 수술 후 항암화학방사선치료의 효과를 분석한 단일기관 연구로, 항암화학방사선치료가 국소재발률 감소뿐만 아니라, 무병생존율 및 전체생존율을 향상시킴을 보여주었다.
덧글달기닫기2021-12-06 14:26:13
등록